



CLINICAL PRACTICE GUIDELINE

Guideline Number: DHMP_DHMC_PG1007

Effective Date: 11/1/2021

**Guideline Subject: Clinical Preventive Health
Recommendations for Adults**

Revision Date: 11/1/2022

Pages: 1 of 7

C. Seals MD
Colorado Board of Medical Examiners

11.4.21

Quality Management Committee Chair

Date

I. PURPOSE:

- To improve physician/practitioner awareness and compliance with effective clinical preventive care
- To improve patient education and to increase the percentage of members who receive recommended clinical preventive care services
- Focused on primary preventive services (immunization, education and counseling, and screening tests) and strategies that have been shown to reduce the likelihood of future adverse outcomes in individuals prior to the onset of symptomatic disease

II. POPULATION:

The guidelines do not cover all possible circumstances, but are a summary of basic preventive services for an average risk, asymptomatic and otherwise healthy adult, and age 18 years and over.

- Preventive care interventions appropriate for those with other levels of risk will vary by individual circumstance and provider judgment will take precedence
- These guidelines are designed to assist the clinician by providing a guide to clinical preventive care, not to replace clinician judgment. Final decisions regarding medical treatment, including preventive care, are made by the physician and the patient
- Interventions listed represent a minimum set of recommended preventive health services
- Physicians/practitioners are encouraged to review the US Preventive Services Task Force (USPSTF) statements regarding Grade Definitions and Levels of Certainty regarding Net Benefit for services <https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-definitions>. The USPSTF discourages the use of services graded D (moderate to high certainty that there is no net benefit or that harms outweigh benefits) and services graded I (current evidence is insufficient to assess the balance of benefits and harms)

III. GUIDELINE:

A. History and Physical Examination: at least annually, at every age

1. Height and weight measurement: baseline height at initial visit and weight at every visit. Consider height at each visit for those >65 years of age.
2. Calculation of Body Mass Index: at every visit.
3. Blood Pressure Measurement: at every visit.
4. 65+ and older individuals assessed annually to confirm if up to date with, or recommended for, osteoporosis screening.

B. Counseling/Education:

Provide health counseling regarding the following:

1. Avoidance of tobacco and/or tobacco cessation
2. Weight loss for obese adults
3. Promotion of a healthy diet
4. Benefits of physical activity
5. Safe Alcohol use

NOTE:

This guideline is designed to assist providers by providing an analytical framework for the evaluation and treatment of patients, and is not intended either to replace a clinician's judgment or to establish a protocol for all patients with a particular condition.



CLINICAL PRACTICE GUIDELINE

Guideline Number: DHMP_DHMC_PG1007

Effective Date: 11/1/2021

**Guideline Subject: Clinical Preventive Health
Recommendations for Adults**

Revision Date: 11/1/2022

Pages: 2 of 7

C. Seals MD
Colorado Board of Medical Examiners

11.4.21

Quality Management Committee Chair

Date

- 6. Sexually transmitted infection prevention
- 7. Risks and symptoms of endometrial cancer to women of average risk at the time of menopause
 - Strongly encourage women to report any unexpected bleeding or spotting to their physicians
- 8. Minimizing exposure to ultraviolet radiation to reduce risk for skin cancer and skin protection. Sunscreen use is encouraged.
- 9. Conduct history and utilize screening tools for the following conditions not covered elsewhere as necessary:
 - a. Birth control/sexual behavior
 - For full recommendations and updates regarding emergency contraception and contraceptive use, refer to <https://www.cdc.gov/reproductivehealth/contraception/mmwr/spr/summary.html>
 - b. Dental health
 - c. Smoking
 - d. Alcohol use
 - e. Injury prevention
- 10. For women of childbearing age:
 - a. Screen for intimate partner violence and provide or refer to intervention services if indicated
 - b. Advise women planning or capable of pregnancy to take 0.4-0.8mg daily folic acid supplement

C. Screening Tests:

Cholesterol:

Screen for lipid disorders with total cholesterol and HDL, or Lipid Panel. If total cholesterol is >200mg/dl or HDL is <40 mg/dl, recommend follow-up lipoprotein.		
Men	<ul style="list-style-type: none"> • 20-35 years if at increased risk for coronary heart disease • 35 years and older 	Screening recommended every 5 years
Women	<ul style="list-style-type: none"> • 20-45 years if at increased risk for coronary heart disease • 45 years and older 	<5 year intervals: If lipid levels are close to warranting therapy >5 year intervals: If low-risk and have repeatedly low or normal lipid levels
Risk Factors: family history of premature heart disease, hypertension, hyperlipidemia, low HDL, diabetes, tobacco use, obesity (BMI>30), age, male gender. For treatment using statins, follow 2017 ACC/AHA guidelines, check full panel. Statins for 1. LDL \geq 190, 2. T2DM with \geq 70, 3. Global risk score \geq 10% (versus 7.5%),		

Cervical Cancer Screening:

Women < 21 years	Women, age 21-29	Women, age 30-65	Women with total hysterectomy
------------------	------------------	------------------	-------------------------------

NOTE:

This guideline is designed to assist providers by providing an analytical framework for the evaluation and treatment of patients, and is not intended either to replace a clinician's judgment or to establish a protocol for all patients with a particular condition.



CLINICAL PRACTICE GUIDELINE

Guideline Number: DHMP_DHMC_PG1007

Effective Date: 11/1/2021

Guideline Subject: Clinical Preventive Health
Recommendations for Adults

Revision Date: 11/1/2022

Pages: 3 of 7

C. Seals MD
Clinical MD Denver, 2018-2019, 2020

111.4.21

Quality Management Committee Chair

Date

No need for screening	Cervical cytology every 3 years	Cytology and human papillomavirus (HPV) co-test every 5 years OR cytology alone every 3 years	<p>Not necessary as long as the cervix is not present.</p> <p>Also, treatment guidelines are based on CV risk, not on absolute LDL guidelines. Treatment is recommended if risk > 7.5%. Would leave this out or use updated guidelines</p> <p>*women who have had total hysterectomy due to dysplasia require screening per DHMP Cervical Cancer Screening Guideline</p>
-----------------------	---------------------------------	---	---

Refer to DHMP Cervical Cancer Screening Guideline for further discussion and details

Breast Cancer Screening:

Females <50 years	Females 50-74 years HEDIS (BCS) specification: ages 52-74	Females over 75 years
<ul style="list-style-type: none"> Screening prior to age 50 should utilize shared decision making between the provider and member. Special consideration should be given to patient context, risk, and values regarding benefit/harm 	<ul style="list-style-type: none"> Biennial mammography Yearly mammography at provider discretion when indicated 	Determine need of further mammography based on shared decision making

Providers should screen women at high risk with one of several screening tools designed to identify increased risk for potentially harmful mutations in breast cancer susceptibility genes. Members with a positive screening test should be referred for genetic counseling and potential BRCA testing if indicated.

Recommended Screening Tools:

National Cancer Institute - The risk calculator is imbedded in the Breast Cancer Risk Assessment Tool
<https://bcrisktool.cancer.gov/calculator.html>

This tool is also endorsed by the CDC
https://www.cdc.gov/cancer/breast/young_women/bringyourbrave/health_care_provider_education/risk-assessment-management-strategies/risk-assessment.htm

NOTE:

This guideline is designed to assist providers by providing an analytical framework for the evaluation and treatment of patients, and is not intended either to replace a clinician's judgment or to establish a protocol for all patients with a particular condition.



CLINICAL PRACTICE GUIDELINE

Guideline Number: DHMP_DHMC_PG1007

Effective Date: 11/1/2021

**Guideline Subject: Clinical Preventive Health
Recommendations for Adults**

Revision Date: 11/1/2022

Pages: 4 of 7

C. Seals MD
Colorado Board of Medical Examiners

111.4.21

Quality Management Committee Chair

Date

Breast Cancer Surveillance Consortium Risk Calculator (BCSC)

<https://tools.bcscc-scc.org/BC5yearRisk/calculator.htm>

<https://tools.bcscc-scc.org/BC5yearRisk/intro.htm>

Risk Factors: age, first degree relative (parent, sibling, or child) with breast, ovarian, tubal, or peritoneal cancer, genetic predisposition, personal history of ovarian cancer or high risk breast biopsy result, history of chest radiation therapy at a young age.

Prostate Cancer Screening:

Men, age 18-54 years	Men, age 55-69 years	Men, age 70+ years
<ul style="list-style-type: none"> Shared decision making will be utilized only in high risk patients to discuss Prostate Specific antigen (PSA) High-risk men will be provided the same screening education and options as men age 50-69, but will start at age 40 for African Americans and age 45 for men not of African American descent 	<ul style="list-style-type: none"> Shared decision making with those of moderate risk, including clear explanation and understanding of the benefits and harms (2018 update) Only offer PSA screening for men who express a clear preference for screening after shared decision making and have a life expectancy of >10 years For men who have chosen PSA screening, screening will be completed every 2 years 	PSA screening and routine discussion of screening is not recommended

Risk Factors: African-American ancestry, and either a brother or father diagnosed with prostate cancer before age 65

Colorectal Cancer Screening:

Men and Women age 45-75 years					75+ years
ONE of the tests listed within the specified timeframe					
Fecal occult blood test (gFOBT) ANNUALLY	FIT-DNA test (immunochemical FIT) ANNUALLY	CT colonography Every FIVE years	Flexible Sigmoidoscopy Every FIVE years	Colonoscopy Every TEN Years	<ul style="list-style-type: none"> Screening is not recommended, but individuals may use shared decision making to determine the need for further screening Screening is NOT recommended after age 86

Risk Factors: diagnosis of colorectal cancer in a first-degree relative, specific genetic syndromes, inflammatory bowel disease, and precancerous polyps.

NOTE:

This guideline is designed to assist providers by providing an analytical framework for the evaluation and treatment of patients, and is not intended either to replace a clinician's judgment or to establish a protocol for all patients with a particular condition.



CLINICAL PRACTICE GUIDELINE

Guideline Number: DHMP_DHMC_PG1007

Effective Date: 11/1/2021

**Guideline Subject: Clinical Preventive Health
Recommendations for Adults**

Revision Date: 11/1/2022

Pages: 5 of 7

C. Seals MD
Colorado Board of Medical Examiners

11.4.21

Quality Management Committee Chair

Date

Other Screenings:

Screening	Age	Description/Action
Alcohol/Substance Misuse/Abuse HEDIS measure: IAD	Adults 18+	<ul style="list-style-type: none"> Screening should be implemented when services for accurate diagnosis, effective treatment, and appropriate care can be offered. Assess history of alcohol and substance abuse Counsel about the effects of alcohol/substance misuse/abuse Recommend that prescription medications be stored in a secure place and that any unused prescription medication is properly disposed of Provide those engaged in risky or hazardous drinking with brief counseling interventions to reduce alcohol misuse Counsel not to drive when under the influence of alcohol/substances, or to ride with anyone under the influence
Depression HEDIS measure: DMS; COA; MPT	All adults, annually including pregnant and post-partum women	<ul style="list-style-type: none"> Utilize screening tools such as the PHQ-2 or PHQ-9 Ensure accurate diagnosis, effective treatment, and appropriate follow-up
Tobacco Use HEDIS Measure IAD	Ask all adults about tobacco use, at every visit	<ul style="list-style-type: none"> Assess readiness to quit and counsel current smokers/tobacco users to stop smoking/using tobacco Offer resources such as the quit line and education regarding tobacco/smoking cessation and risks associated with tobacco use Provide behavioral interventions and US FDA approved pharmacotherapy to nonpregnant adults who use tobacco.
Obesity	All adults, at every periodic health evaluation	<ul style="list-style-type: none"> Members with a body mass index (BMI) of 30 kg/m² or higher (or BMI >25 with co-morbidities) to intensive, multicomponent behavioral interventions to promote sustained weight loss Counsel on the benefits of physical activity and a healthy diet to maintain an appropriate weight for height
HIV	15-65 years	<ul style="list-style-type: none"> Screen all pregnant persons, including those who present in labor or at delivery whose HIV status is unknown Counsel about risk factor reduction Routine serology screening for adults ages 15-65 Screening for adults > 65 years who are at increased risk
Intimate Partner Violence	18+ years; special attention to women of childbearing age	<ul style="list-style-type: none"> Assess and screen for physical and behavioral signs of abuse and neglect Provide or refer those who screen positive to intervention services
Hepatitis C	18- 79	<ul style="list-style-type: none"> Counsel about risk factor reductionScreen persons younger than 18 or older than 79 who are at higher risk for infection (eg, those w/ history of or current IV drug use)

NOTE:

This guideline is designed to assist providers by providing an analytical framework for the evaluation and treatment of patients, and is not intended either to replace a clinician's judgment or to establish a protocol for all patients with a particular condition.



CLINICAL PRACTICE GUIDELINE

Guideline Number: DHMP_DHMC_PG1007

Effective Date: 11/1/2021

Guideline Subject: Clinical Preventive Health
Recommendations for Adults

Revision Date: 11/1/2022

Pages: 6 of 7

C. Seals, MD
Quality Management Committee Chair

11.4.21

Quality Management Committee Chair

Date

Screening	Age	Description/Action
		<ul style="list-style-type: none"> • Periodic testing of high risk members
Lung Cancer	50-80 years of age with a 20 pack-year smoking history and currently smoke or have quit within the past 15 years	<ul style="list-style-type: none"> • Use shared decision making and explanation of risk/benefit to determine if screening will be done • If member elects screening, complete annual screening with low-dose CT • Discontinue screening once the member has not smoked for 15 years or develops a health problem that substantially limits life expectancy or ability/willingness to have curative lung surgery
Skin Cancer	18+ years	<ul style="list-style-type: none"> • Inspect skin for abnormalities when performing physical exam • Educate patients at-risk about skin cancer, including the ABCDE guidelines to check all skin lesions • Counsel to limit exposure to the sun, to fully cover skin with clothing and hats, and to use sun block • Discourage indoor tanning bed use
Immunizations	18+ years	<ul style="list-style-type: none"> • Administer immunizations in accordance with the ACIP recommended immunization schedule, refer to the DHMP immunization guideline for further details
Sexually Transmitted Infections	18+ years	<ul style="list-style-type: none"> • Assess sexual history and counsel on effective ways to reduce risk based on history and risk factors • Chlamydia and Gonorrhea: screen all sexually active females ≤24 years annually, at age 24+ only screen if at risk • Syphilis: screen if at risk • HPV: Recommend HPV vaccination for everyone 26 and under if not previously vaccinated. Vaccination is recommended at 11 or 12 years old and can begin as early as 9.

IV. REFERENCES:

A and B Recommendations: United States Preventive Services Taskforce. (n.d.). Retrieved September 2021, from <https://www.uspreventiveservicestaskforce.org/Page/Name/uspstf-a-and-b-recommendations-by-date/>

CDC - Summary - US SPR - Reproductive Health. (2020, April 01). Retrieved September 2021, from <https://www.cdc.gov/reproductivehealth/contraception/mmwr/spr/summary.html>

NOTE:

This guideline is designed to assist providers by providing an analytical framework for the evaluation and treatment of patients, and is not intended either to replace a clinician's judgment or to establish a protocol for all patients with a particular condition.



CLINICAL PRACTICE GUIDELINE

Guideline Number: DHMP_DHMC_PG1007

Effective Date: 11/1/2021

**Guideline Subject: Clinical Preventive Health
Recommendations for Adults**

Revision Date: 11/1/2022

Pages: 7 of 7

C. Seals MD
Quality Management Committee Chair

11.4.21

Quality Management Committee Chair

Date

CDC- Summary Immunization Schedules (2021, February 12). Retrieved September 2021 from <http://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html>

Early Detection in Prostate Cancer. (2018). Retrieved September 2021, from <http://www.aunanet.org/guidelines/prostate-cancer-early-detection-guideline>

GoffJr, D., David C. GoffJr Search for more papers by this author, Lloyd-Jones, D., Donald M. Lloyd-Jones Search for more papers by this author, Bennett, G., Glen Bennett *Ex-Officio Members. Al., E. (2013, November 12). 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Retrieved September 2021, from <https://www.ahajournals.org/doi/full/10.1161/01.cir.0000437741.48606.98>

Search Results: United States Preventive Services Taskforce. Multiple Authors (2016-2020). Retrieved September 2021, from <https://www.uspreventiveservicestaskforce.org/BrowseRec/Index/browse-recommendations>

U.S. Preventive Services: Prevention TaskForce. (n.d.). Retrieved September 2021, from <https://epss.ahrq.gov/PDA/index.jsp>

NOTE:

This guideline is designed to assist providers by providing an analytical framework for the evaluation and treatment of patients, and is not intended either to replace a clinicians judgment or to establish a protocol for all patients with a particular condition.

How to Be Reasonably Certain That a Woman is Not Pregnant

A health-care provider can be reasonably certain that a woman is not pregnant if she has no symptoms or signs of pregnancy and meets any one of the following criteria:

- is ≤ 7 days after the start of normal menses
- has not had sexual intercourse since the start of last normal menses
- has been correctly and consistently using a reliable method of contraception
- is ≤ 7 days after spontaneous or induced abortion
- is within 4 weeks postpartum
- is fully or nearly fully breastfeeding (exclusively breastfeeding or the vast majority [$\geq 85\%$] of feeds are breastfeeds), amenorrheic, and < 6 months postpartum

In situations in which the health-care provider is uncertain whether the woman might be pregnant, the benefits of starting the implant, depot medroxyprogesterone acetate (DMPA), combined hormonal contraceptives and progestin-only pills likely exceed any risk; therefore, starting the method should be considered at any time, with a follow-up pregnancy test in 2-4 weeks. For IUD insertion, in situations in which the health-care provider is not reasonably certain that the woman is not pregnant, the woman should be provided with another contraceptive method to use until the health-care provider can be reasonably certain that she is not pregnant and can insert the IUD.

When to Start Using Specific Contraceptive Methods

Contraceptive method	When to start (if the provider is reasonably certain that the woman is not pregnant)	Additional contraception (i.e., back up) needed	Examinations or tests needed before initiation ¹
Copper-containing IUD	Anytime	Not needed	Bimanual examination and cervical inspection ²
Levonorgestrel-releasing IUD	Anytime	If > 7 days after menses started, use back-up method or abstain for 7 days.	Bimanual examination and cervical inspection ²
Implant	Anytime	If > 5 days after menses started, use back-up method or abstain for 7 days.	None
Injectable	Anytime	If > 7 days after menses started, use back-up method or abstain for 7 days.	None
Combined hormonal contraceptive	Anytime	If > 5 days after menses started, use back-up method or abstain for 7 days.	Blood pressure measurement
Progestin-only pill	Anytime	If > 5 days after menses started, use back-up method or abstain for 2 days.	None

Abbreviations: BMI = body mass index; IUD = intrauterine device; STD = sexually transmitted disease; U.S. MEC = U.S. Medical Eligibility Criteria for Contraceptive Use

¹ Weight (BMI) measurement is not needed to determine medical eligibility for any methods of contraception because all methods can be used (U.S. MEC 1) or generally can be used (U.S. MEC 2) among obese women. However, measuring weight and calculating BMI (weight [kg]/height [m²] at baseline might be helpful for monitoring any changes and counseling women who might be concerned about weight change perceived to be associated with their contraceptive method.

² Most women do not require additional STD screening at the time of IUD insertion. If a woman with risk factors for STDs has not been screened for gonorrhea and chlamydia according to CDC's STD Treatment Guidelines (<http://www.cdc.gov/std/treatment>), screening can be performed at the time of IUD insertion, and insertion should not be delayed. Women with current purulent cervicitis or chlamydial infection or gonococcal infection should not undergo IUD insertion (U.S. MEC 4).

Routine Follow-Up After Contraceptive Initiation*

Action	Contraceptive Method				
	Cu-IUD or LNG-IUD	Implant	Injectable	CHC	POP
General Follow-Up					
Advise women to return at any time to discuss side effects or other problems or if they want to change the method. Advise women using IUDs, implants, or injectables when the IUD or implant needs to be removed or when reinjection is needed. No routine follow-up visit is required.	X	X	X	X	X
Other Routine Visits					
Assess the woman's satisfaction with her current method and whether she has any concerns about method use.	X	X	X	X	X
Assess any changes in health status, including medications, that would change the method's appropriateness for safe and effective continued use based on the U.S. MEC (i.e., category 3 and 4 conditions and characteristics).	X	X	X	X	X
Consider performing an examination to check for the presence of IUD strings.	X	–	–	–	–
Consider assessing weight changes and counseling women who are concerned about weight change perceived to be associated with their contraceptive method.	X	X	X	X	X
Measure blood pressure.	–	–	–	X	–
Abbreviations: CHC = combined hormonal contraceptive; Cu-IUD = copper-containing intrauterine device; IUD = intrauterine device; LNG-IUD = levonorgestrel-releasing intrauterine device; POP = progestin-only pills; U.S. MEC = <i>U.S. Medical Eligibility Criteria for Contraceptive Use</i> , 2016.					

*These recommendations address when routine follow-up is recommended for safe and effective continued use of contraception for healthy women. The recommendations refer to general situations and might vary for different users and different situations. Specific populations that might benefit from frequent follow-up visits include adolescents, those with certain medical conditions or characteristics, and those with multiple medical conditions.
Source: For full recommendations and updates, see the U.S. Selected Practice Recommendations for Contraceptive Use webpage at <http://www.cdc.gov/reproductivehealth/unintendedpregnancy/usspr.htm>

FINAL Guideline Clinical Preventative Health Recommendations for Adults 2021

Final Audit Report


2021-11-04

Created:	2021-11-04
By:	Jacqueline De La Torre (Jacqueline.DeLaTorre@dhha.org)
Status:	Signed
Transaction ID:	CBJCHBCAABAARQ_KzMkHXoWw-Crr6bMiOj88EJVIN0A_

"FINAL Guideline Clinical Preventative Health Recommendations for Adults 2021" History

 Document created by Jacqueline De La Torre (Jacqueline.DeLaTorre@dhha.org)


2021-11-04 - 6:06:51 PM GMT

 Document emailed to C Seals MD (christine.seals@dhha.org) for signature

2021-11-04 - 6:08:13 PM GMT

 Email viewed by C Seals MD (christine.seals@dhha.org)

2021-11-04 - 6:14:10 PM GMT

 Document e-signed by C Seals MD (christine.seals@dhha.org)

Signature Date: 2021-11-04 - 6:15:46 PM GMT - Time Source: server

 Agreement completed.

2021-11-04 - 6:15:46 PM GMT